International Journal of Molecular Sciences

Journal Browser

► Journal Browser

Special Issue Editors

Dr. María Esperanza Cerdán

E-Mail Website
Guest Editor

EXPRELA Group, Centro de Investigacións Científicas Avanzadas (CICA), Departamento de Bioloxía, Facultade de Ciencias, INIBIC-Universidade da Coruña, Campus de A Coruña, 15071 A Coruña, Spain
Interests: control of gene expression through various mechanisms: transcription factors, lncRNAs, and interactomes, developing projects in this line oriented to biomedicine; focused in lncRNA-HMGB interactions that can be detected in early stages of cancer disease, as well as deepening knowledge of the sequences involved in the interaction between both types of molecules, looking for possible therapeutic targets
Special Issues, Collections and Topics in MDPI journals

Dr. Mónica Lamas-Maceiras

E-Mail Website
Guest Editor

EXPRELA Group, Centro de Investigacións Científicas Avanzadas CICA, Departamento de Bioloxía, Facultad de Ciencias, INIBIC—Universidade de A Coruña, Campus A Coruna, 15071 La Coruna, Spain
Interests: proteins for tumor cell apoptosis and inhibition of metastasis

Special Issue Information

Dear Colleagues,

"Recent Molecular Biology on Ovarian Cancer and Prostate Cancer" is a Special Issue that explores the latest advancements in the understanding of molecular mechanisms, diagnosis and therapy of these two important cancers. The issue includes a range of articles that cover topics such as the use of advanced imaging techniques to identify aggressive tumors; the development of new biomarkers for early detection; the role of ncRNAs in oncogenesis; the use of genetic screening for an earlier diagnosis or high-risk identification; the discovery of new drug targets; and the potential of immunotherapy as a treatment option. These articles underscore the importance of precision medicine in the management of these cancers, as well as the importance of a multidisciplinary research approach to tackle these diseases.

Overall, "Recent Molecular Biology on Ovarian Cancer and Prostate Cancer" provides a comprehensive overview of the latest research on these two important diseases, and it is a valuable resource for researchers and anyone interested in advancing our understanding of cancer biology. We welcome the submission of original articles, reviews, and communication.

This Special Issue is supervised by Dr. María-Esperanza Cerdán and Dr. Mónica Lamas Maceiras, and assisted by our Topical Advisory Panel Members Dr. Ángel Vizoso Vázquez and Dr. Aida Barreiro Alonso (University of A Coruña).

Dr. María Esperanza Cerdán
Dr. Mónica Lamas-Maceiras
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

ovarian cancer
prostate cancer
ncRNAs
genetic screening
advanced imaging techniques
biomarkers
immunotherapy

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

13 pages, 3779 KiB

Open AccessArticle

The Effect of HMGB1 and HMGB2 on Transcriptional Regulation Differs in Neuroendocrine and Adenocarcinoma Models of Prostate Cancer

by Martín Salamini-Montemurri, Ángel Vizoso-Vázquez, Aida Barreiro-Alonso, Lidia Lorenzo-Catoira, Esther Rodríguez-Belmonte, María-Esperanza Cerdán and Mónica Lamas-Maceiras

Int. J. Mol. Sci. 2024, 25(6), 3106; https://doi.org/10.3390/ijms25063106 - 07 Mar 2024

Viewed by 701

Abstract

Human high-mobility group-B (HMGB) proteins regulate gene expression in prostate cancer (PCa), a leading cause of oncological death in men. Their role in aggressive PCa cancers, which do not respond to hormonal treatment, was analyzed. The effects of HMGB1 and HMGB2 silencing upon the expression of genes previously related to PCa were studied in the PCa cell line PC-3 (selected as a small cell neuroendocrine carcinoma, SCNC, PCa model not responding to hormonal treatment). A total of 72% of genes analyzed, using pre-designed primer panels, were affected. HMGB1 behaved mostly as a repressor, but HMGB2 as an activator. Changes in SERPINE1, CDK1, ZWINT, and FN1 expression were validated using qRT-PCR after HMGB1 silencing or overexpression in PC-3 and LNCaP (selected as an adenocarcinoma model of PCa responding to hormonal treatment) cell lines. Similarly, the regulatory role of HMGB2 upon SERPINE1, ZWINT, FN1, IGFPB3, and TYMS expression was validated, finding differences between cell lines. The correlation between the expression of HMGB1, HMGB2, and their targets was analyzed in PCa patient samples and also in PCa subgroups, classified as neuroendocrine positive or negative, in public databases. These results allow a better understanding of the role of HMGB proteins in PCa and contribute to find specific biomarkers for aggressive PCa. Full article

(This article belongs to the Special Issue Recent Molecular Biology on Ovarian Cancer and Prostate Cancer)

► Show Figures

Graphical abstract

Review

Jump to: Research

28 pages, 1627 KiB

Open AccessReview

Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements

by Valéria Tavares, Inês Soares Marques, Inês Guerra de Melo, Joana Assis, Deolinda Pereira and Rui Medeiros

Int. J. Mol. Sci. 2024, 25(3), 1845; https://doi.org/10.3390/ijms25031845 - 03 Feb 2024

Viewed by 1862

Abstract

Ovarian cancer (OC) is the female genital malignancy with the highest lethality. Patients present a poor prognosis mainly due to the late clinical presentation allied with the common acquisition of chemoresistance and a high rate of tumour recurrence. Effective screening, accurate diagnosis, and personalised multidisciplinary treatments are crucial for improving patients’ survival and quality of life. This comprehensive narrative review aims to describe the current knowledge on the aetiology, prevention, diagnosis, and treatment of OC, highlighting the latest significant advancements and future directions. Traditionally, OC treatment involves the combination of cytoreductive surgery and platinum-based chemotherapy. Although more therapeutical approaches have been developed, the lack of established predictive biomarkers to guide disease management has led to only marginal improvements in progression-free survival (PFS) while patients face an increasing level of toxicity. Fortunately, because of a better overall understanding of ovarian tumourigenesis and advancements in the disease’s (epi)genetic and molecular profiling, a paradigm shift has emerged with the identification of new disease biomarkers and the proposal of targeted therapeutic approaches to postpone disease recurrence and decrease side effects, while increasing patients’ survival. Despite this progress, several challenges in disease management, including disease heterogeneity and drug resistance, still need to be overcome. Full article

(This article belongs to the Special Issue Recent Molecular Biology on Ovarian Cancer and Prostate Cancer)

► Show Figures